-
Something wrong with this record ?
Arylazopyrazole AAP1742 inhibits CDKs and induces apoptosis in multiple myeloma cells via Mcl-1 downregulation
R. Jorda, J. Navrátilová, Z. Hušková, E. Schütznerová, P. Cankař, M. Strnad, V. Kryštof,
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
24803299
DOI
10.1111/cbdd.12330
Knihovny.cz E-resources
- MeSH
- Enzyme Activation drug effects MeSH
- Apoptosis drug effects MeSH
- Azo Compounds chemistry pharmacology MeSH
- Cyclin-Dependent Kinase 9 antagonists & inhibitors metabolism MeSH
- Down-Regulation drug effects MeSH
- Phosphorylation drug effects MeSH
- Humans MeSH
- RNA, Messenger metabolism MeSH
- Mitochondria metabolism MeSH
- Multiple Myeloma metabolism pathology MeSH
- Cell Line, Tumor MeSH
- Myeloid Cell Leukemia Sequence 1 Protein genetics metabolism MeSH
- Antineoplastic Agents chemistry pharmacology MeSH
- Proto-Oncogene Proteins c-bcl-2 genetics metabolism MeSH
- Pyrazoles chemistry pharmacology MeSH
- RNA Polymerase II metabolism MeSH
- X-Linked Inhibitor of Apoptosis Protein genetics metabolism MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Inhibitors of cyclin-dependent kinases 9 have been developed as potential anticancer drugs for the treatment of multiple myeloma. We have previously prepared a library of arylazo-3,5-diaminopyrazole inhibitors of CDKs. Here, we describe a novel member, AAP1742 (CDK9 inhibition with IC(50) = 0.28 μm), that reduces the viability of multiple myeloma cell lines in low micromolar concentrations. Consistent with inhibition of CDK9, AAP1742 decreases the phosphorylation of RNA polymerase II and inhibits mRNA synthesis of anti-apoptotic proteins Mcl-1, Bcl-2, and XIAP, followed by apoptosis in the RPMI-8226 cell line in a dose- and a time-dependent manner. These results are consistent with the biochemical profile of AAP1742 and further suggest cellular inhibition of CDK9 as a possible target for anticancer drugs.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15023435
- 003
- CZ-PrNML
- 005
- 20150730104402.0
- 007
- ta
- 008
- 150709s2014 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/cbdd.12330 $2 doi
- 035 __
- $a (PubMed)24803299
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Jorda, Radek $u Laboratory of Growth Regulators, Centre of the Region Haná for Biotechnological and Agricultural Research, Institute of Experimental Botany ASCR and Palacký University, Šlechtitelů 11, 783 71, Olomouc, Czech Republic; Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Žlutý kopec 7, 656 53, Brno, Czech Republic.
- 245 10
- $a Arylazopyrazole AAP1742 inhibits CDKs and induces apoptosis in multiple myeloma cells via Mcl-1 downregulation / $c R. Jorda, J. Navrátilová, Z. Hušková, E. Schütznerová, P. Cankař, M. Strnad, V. Kryštof,
- 520 9_
- $a Inhibitors of cyclin-dependent kinases 9 have been developed as potential anticancer drugs for the treatment of multiple myeloma. We have previously prepared a library of arylazo-3,5-diaminopyrazole inhibitors of CDKs. Here, we describe a novel member, AAP1742 (CDK9 inhibition with IC(50) = 0.28 μm), that reduces the viability of multiple myeloma cell lines in low micromolar concentrations. Consistent with inhibition of CDK9, AAP1742 decreases the phosphorylation of RNA polymerase II and inhibits mRNA synthesis of anti-apoptotic proteins Mcl-1, Bcl-2, and XIAP, followed by apoptosis in the RPMI-8226 cell line in a dose- and a time-dependent manner. These results are consistent with the biochemical profile of AAP1742 and further suggest cellular inhibition of CDK9 as a possible target for anticancer drugs.
- 650 _2
- $a protinádorové látky $x chemie $x farmakologie $7 D000970
- 650 _2
- $a apoptóza $x účinky léků $7 D017209
- 650 _2
- $a azosloučeniny $x chemie $x farmakologie $7 D001391
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a cyklin-dependentní kinasa 9 $x antagonisté a inhibitory $x metabolismus $7 D042863
- 650 _2
- $a down regulace $x účinky léků $7 D015536
- 650 _2
- $a aktivace enzymů $x účinky léků $7 D004789
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mitochondrie $x metabolismus $7 D008928
- 650 _2
- $a mnohočetný myelom $x metabolismus $x patologie $7 D009101
- 650 _2
- $a protein MCL-1 $x genetika $x metabolismus $7 D064549
- 650 _2
- $a fosforylace $x účinky léků $7 D010766
- 650 _2
- $a protoonkogenní proteiny c-bcl-2 $x genetika $x metabolismus $7 D019253
- 650 _2
- $a pyrazoly $x chemie $x farmakologie $7 D011720
- 650 _2
- $a RNA-polymerasa II $x metabolismus $7 D012319
- 650 _2
- $a messenger RNA $x metabolismus $7 D012333
- 650 _2
- $a X-vázaný inhibitor apoptózy $x genetika $x metabolismus $7 D051636
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Navrátilová, Jana
- 700 1_
- $a Hušková, Zlata
- 700 1_
- $a Schütznerová, Eva
- 700 1_
- $a Cankař, Petr
- 700 1_
- $a Strnad, Miroslav
- 700 1_
- $a Kryštof, Vladimír
- 773 0_
- $w MED00173265 $t Chemical biology & drug design $x 1747-0285 $g Roč. 84, č. 4 (2014), s. 402-8
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/24803299 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20150709 $b ABA008
- 991 __
- $a 20150730104450 $b ABA008
- 999 __
- $a ok $b bmc $g 1083772 $s 906428
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 84 $c 4 $d 402-8 $i 1747-0285 $m Chemical biology & drug design $n Chem Biol Drug Des $x MED00173265
- LZP __
- $a Pubmed-20150709
